Drug Profile
LY 3000328
Alternative Names: LY3000328Latest Information Update: 06 May 2014
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 30 Apr 2014 No development reported - Phase-I for Undefined indication in USA (PO)
- 01 Feb 2012 Phase-I clinical trials in Undefined indication in USA (PO)
- 18 Jan 2012 Preclinical trials in Undefined indication in USA (PO)